Note: Descriptions are shown in the official language in which they were submitted.
CA 02978659 2017-09-05
WO 2016/156404
PCT/EP2016/056926
1
"Eukaryotic expression vectors comprising regulatory elements of the globin
gene
clusters"
FIELD OF THE INVENTION
The present invention pertains to novel expression cassettes which can be used
to
enhance the production yield of a protein of interest. The expression
cassettes
comprise expression regulation elements of the human globin gene clusters, in
particular the promoter of the human Ay globin and the locus control region of
the
human 13-globin or a-globin gene cluster. The present invention in particular
provides
an expression cassette comprising such globin expression regulation elements.
BACKGROUND OF THE INVENTION
Recombinant protein production is a major aspect of the biotechnical industry
of today.
It is gaining more and more importance as the number of applications requiring
high
amounts of high-quality proteins increase on the market. Food production and
in
particular pharmacology are two main areas where the need for recombinant
proteins
steadily increases. Higher production efficiencies and consequently lower
costs of the
final product are needed for obtaining a commercially viable process.
However, at the same time a high product quality and compatibility with human
applications is essential. More and more applications required recombinant
production
of the proteins in eukaryotic cells, in particular in higher eukaryotic cells.
Especially
proteins carrying post-translational modifications such a glycosylation
(glycoproteins)
significantly differ when expressing them in prokaryotic cell systems such as
E. coil or
eukaryotic cell systems such as in particular human cell lines. These
differences in
many cases markedly affect the biological activity as well as the
immunogenicity of the
produced proteins. However, many expression systems using higher eukaryotic
cell
CA 02978659 2017-09-05
WO 2016/156404
PCT/EP2016/056926
2
lines suffer from a rather low expression rate of the desired protein,
resulting in low
yields and high costs of the recombinant protein.
Therefore, there is a need in the art to provide novel means and methods for
increasing
the yield of recombinant protein production, especially when using eukaryotic
expression cell lines.
SUMMARY OF THE INVENTION
As demonstrated by the present invention, certain elements of the human globin
gene
clusters can be combined to provide an expression cassette which enables
stable and
high expression of polypeptides of interest in eukaryotic cells. In
particular, the
combination of specific parts of the locus control region of the 13-globin
gene cluster or
the a-globin gene cluster with the Ay globin promoter and optionally also the
Ay globin 3'
enhancer forms an expression cassette with surprisingly high and stable
expression
rates.
Therefore, the present invention provides in a first aspect a method for
recombinantly
producing a polypeptide of interest, comprising the steps of
(a) providing a host cell which comprises an expression cassette comprising,
functionally linked to each other,
(i) a locus control region comprising at least a functional part of the locus
control region of the human 13-globin gene cluster or the human a-globin
2 0 gene cluster;
(ii) a promoter region comprising at least a functional part of the promoter
of
the human Ay globin gene; and
(iii) a coding region comprising a nucleic acid sequence encoding the
polypeptide of interest;
(b) culturing the host cell under conditions at which the host cell expresses
the
polypeptide of interest; and
(c) isolating the polypeptide of interest.
In a second aspect, the present invention provides an expression cassette
comprising,
functionally linked to each other,
(i) a locus control region comprising at least a functional part of the locus
control region of the human 13-globin gene cluster or the human a-globin
gene cluster;
CA 02978659 2017-09-05
WO 2016/156404
PCT/EP2016/056926
3
(ii) a promoter region comprising at least a functional part of the promoter
of the
human Ay globin gene;
(iii) optionally a coding region;
(iv) a transcription terminator region; and
(v) an enhancer region comprising at least a functional part of the 3 enhancer
of
the human Ay globin gene;
wherein the expression cassette does not comprise a nucleic acid sequence
coding for
the entire human Ay globin.
In a third aspects, the present invention provides a vector comprising the
expression
cassette according to the second aspect and a host cell comprising said
expression
cassette or said vector.
Other objects, features, advantages and aspects of the present invention will
become
apparent to those skilled in the art from the following description and
appended claims.
It should be understood, however, that the following description, appended
claims, and
specific examples, which indicate preferred embodiments of the application,
are given
by way of illustration only. Various changes and modifications within the
spirit and
scope of the disclosed invention will become readily apparent to those skilled
in the art
from reading the following.
DEFINITIONS
As used herein, the following expressions are generally intended to preferably
have the
meanings as set forth below, except to the extent that the context in which
they are
used indicates otherwise.
The expression "comprise", as used herein, besides its literal meaning also
includes
and specifically refers to the expressions "consist essentially of" and
"consist of". Thus,
the expression "comprise" refers to embodiments wherein the subject-matter
which
"comprises" specifically listed elements does not comprise further elements as
well as
embodiments wherein the subject-matter which "comprises" specifically listed
elements
may and/or indeed does encompass further elements. Likewise, the expression
"have"
is to be understood as the expression "comprise", also including and
specifically
3 0 referring to the expressions "consist essentially of" and "consist of".
The term "nucleic acid" as used herein refers to a ribonucleotide or
desoxyribonucleotide polymer. A nucleic acid may be RNA or DNA. It may be
composed of a single polymer strand or it may be double-stranded. The nucleic
acid
CA 02978659 2017-09-05
WO 2016/156404
PCT/EP2016/056926
4
may be of natural, recombinant or synthetic origin. In preferred embodiments,
a nucleic
acid is a double-stranded DNA.
An "expression cassette" is a nucleic acid construct, generated or
synthesized, with
nucleic acid elements that are capable of effecting expression of a structural
gene in
hosts that are compatible with such sequences. Expression cassettes include at
least a
promoter and optionally, transcription termination signals. Typically, the
expression
cassette includes a nucleic acid to be transcribed and a promoter. Additional
factors
helpful in effecting expression may also be used as described herein. For
example, an
expression cassette can also include nucleotide sequences that encode a signal
sequence that directs secretion of an expressed protein from the host cell. An
expression cassette preferably is part of an expression vector. Host cells
which shall be
used for expression of the nucleic acid to be transcribed are transformed or
transfected
with the expression vector. To allow selection of transformed cells comprising
the
constructs, a selectable marker gene can be conveniently included in the
expression
vectors. A person having skill in the art will recognize that this vector
component can
be modified without substantially affecting its function.
The expression "functionally linked" means that two or more elements of an
expression
cassette are linked to one another in such a way that their function is
coordinated and
allows expression of the coding sequence (e.g. the coding region). By way of
example,
a promoter is functionally linked to a coding sequence when it is capable of
ensuring
expression of said coding sequence. The construction of an expression cassette
according to the invention and the assembly of its various elements can be
carried out
using techniques well known to those skilled in the art, in particular those
described in
Sambrook et al. (1989, Molecular Cloning: A Laboratory Manual, Nolan C. ed.,
New
York: Cold Spring Harbor Laboratory Press).
The terms "upstream" and "downstream" as used herein refer to the position of
a
nucleic acid element or sequence on a nucleic acid molecule with respect to
another
nucleic acid element or sequence on said nucleic acid molecule. "Upstream"
refers to a
position which is nearer to the 5' end of the nucleic acid molecule and
"downstream"
refers to a position which is nearer to the 3' end of the nucleic acid
molecule. In case of
double-stranded nucleic acids, in particular DNA, that strand of the nucleic
acid which
is used as matrix for transcription of an RNA such as an mRNA, i.e. the sense
strand,
is used to determine the 5' end and the 3' end of the nucleic acid. Hence,
"upstream" is
in the direction of the 5' end of the sense strand while "downstream" is in
the direction
of the 3' end of the sense strand.
A "homologue" of a target nucleic acid sequence or amino acid sequence shares
a
homology or identity of at least 75 %, more preferably at least 80 %, at least
85 %, at
least 90 %, at least 93 %, at least 95 %, at least 96 %, at least 97 %, at
least 98 % or at
CA 02978659 2017-09-05
WO 2016/156404
PCT/EP2016/056926
least 99 % with said target nucleic acid sequence or amino acid sequence. A
"homology" or "identity" of an amino acid sequence or nucleotide sequence is
preferably determined according to the invention over the entire length of the
target
sequence or over the entire length of the indicated part of the target
sequence. When
5 referring to a specific nucleic acid sequence or amino acid sequence, the
present
invention generally also encompasses homologues of said nucleic acid sequence
or
amino acid sequence, respectively. A homologue of a target nucleic acid
sequence or
amino acid sequence in particular is a functional homologue which has the same
or
substantially the same functions and activities of the target nucleic acid
sequence or
amino acid sequence from which it is derived.
A "promoter" is a nucleic acid sequence which allows and controls
transcription of a
nucleic acid sequence functionally linked thereto, in particular a coding
sequence. A
promoter contains a recognition sequence for binding RNA polymerase and
includes or
is functionally linked to a transcription initiation site. The promoter may be
an inducible
promoter which is only active in the presence (or absence) of a specific
signal, or it
may be constitutively active. The activity of the promoter may be further
regulated by
regulatory elements such as locus control regions and enhancer elements.
A "coding sequence" is a nucleic acid sequence encoding a gene product such as
a
polypeptide or RNA.
A "part" of a nucleic acid element in particular comprises at least 5 nucleic
acids,
preferably at least 10, at least 15, at least 20, at least 30 or at least 50
nucleic acids of
said nucleic acid element. A "part" of a nucleic acid element in particular
comprises at
least 5 consecutive nucleotides, preferably at least 10, at least 15, at least
20, at least
or at least 50 consecutive nucleotides of said nucleic acid element. In
particular, it
25 comprises at least 1 %, preferably at least 2 %, at least 3 %, at least
5 %, at least 7.5
%, at least 10 %, at least 15 %, at least 20 % or at least 25 % of said
nucleic acid
element. A "functional part" of a nucleic acid element is a part of said
element which is
capable of performing the intended function of the element. For example, a
functional
part of a locus control region, promoter or 3' enhancer is capable of
modulating, in
3 0 particular enhancing the expression of a coding region to which it is
functionally linked.
A part of a nucleic acid element in particular refers to a functional part of
said nucleic
acid element.
A "peptide" or "polypeptide" as used herein refers to a polypeptide chain
comprising at
least 5 amino acids. A peptide or polypeptide preferably comprises at least
10, at least
15, at least 20, at least 25, at least 30 or at least 35 amino acids. The term
"peptide" or
"polypeptide" as used herein also refers to proteins, including peptides,
polypeptides
and proteins which were post-translationally modified. In particular, the term
peptide or
CA 02978659 2017-09-05
WO 2016/156404
PCT/EP2016/056926
6
polypeptide includes glycosylated peptides and glycoproteins. The terms
"peptide" and
"polypeptide" are used interchangeably herein.
A part of a peptide, polypeptide or protein preferably comprises at least 3
consecutive
amino acids of said peptide, polypeptide or protein, preferably at least 5, at
least 10, at
least 15 or at least 20 consecutive amino acids of said protein.
The term "pharmaceutical composition" and similar terms particularly refers to
a
composition suitable for administering to a human, i.e., a composition
containing
components which are pharmaceutically acceptable. Preferably, a pharmaceutical
composition comprises an active compound or a salt or prodrug thereof together
with a
1 0 carrier, diluent or pharmaceutical excipient such as buffer,
preservative and tonicity
modifier.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to an expression cassette comprising at
least part of a
locus control region of a human globin gene cluster and a human Ay globin
promoter.
Hemoglobin is a metalloprotein in the blood of humans and animals which
enables the
transport of oxygen and carbon dioxide. Hemoglobin is a multi-subunit globular
protein
comprised of four subunits (globins), each consisting of a polypeptide chain
closely
associated with a heme group which carries an iron ion. There are several
different
types of globin subunits and the subunit composition of hemoglobin changes
throughout life. For example, the human fetus has hemoglobin F composed of two
globin a and two globin y (02Y2), while in the adult hemoglobin A with two
globin a and
two globin 13(02132) predominates. The different globin polypeptides are
expressed by
the human globin gene clusters which are responsible for expression of the
different
subunits in the different developmental states of the human being. The human 3-
globin
gene cluster comprises a locus control region and five different globin genes,
i.e. the E-,
Gy_ , A
6- and 3-globin gene. Likewise, the a-globin gene cluster also comprises a
locus control region and the 4-, a2-, al- and 0-globin genes. Figure 1 shows
the
structure of the human a- and 3-globin gene clusters. Each separate globin
gene within
the gene cluster has its own specific promoter and enhancer sequences which
control
the expression of the coding sequence of the respective globin subunit.
However,
these promoters are themselves regulated by the locus control region. In
particular, the
locus control region is capable of activating or inactivating the promoters
and this
activation pattern changes throughout the lifetime. Both locus control regions
(one in
the a-globin gene cluster and one in the 3-globin gene cluster) hence
orchestrate the
expression of the different globin genes during development, resulting in the
specific
subunit composition of the different hemoglobin proteins.
CA 02978659 2017-09-05
WO 2016/156404
PCT/EP2016/056926
7
The locus control regions comprise several DNase I hypersensitivity sites (HS)
which
are responsible for activation and inactivation of the promoters. It has been
found that,
for example, HS2 of the 3-globin gene cluster controls the activity of the Ay
globin
promoter. HS2 of the 3-globin gene cluster can be further subdivided into a
core region
and modulatory subdomains. The core region is that part of HS2 which is mainly
responsible for activation of the globin promoter. The modulatory subdomains
M1 to
M5 modulate the effect of the core domain, either positively or negatively.
The core
region is positioned between modulatory subdomains M1 and M2, with M3 to M5
following thereafter. In particular M1 and M2 further enhance the activating
effect of the
core region on the Ay globin promoter.
It was now found that the use of expression elements of the human globin gene
clusters provide for a stable and high expression of a target product such as
a
polypeptide of interest in eukaryotic cells, in particular in human blood
cells or cells
derived therefrom. The present invention provides an expression cassette
comprising
at least a functional part of the human Ay globin promoter and at least a
functional part
of a locus control region of the human a-globin or 3-globin gene cluster. The
expression cassette further comprises a coding region which contains a nucleic
acid
sequence encoding a polypeptide of interest and/or a cloning site for
introduction of
such a coding region. The expression cassette may further comprise an enhancer
region comprising at least a functional part of a 3' enhancer of the human Ay
globin
gene. The locus control region, promoter and 3' enhancer are all positioned in
the
expression cassette so that they can modulate and in particular enable and
enhance
the expression of the coding region. The expression cassette also may comprise
a
transcription terminator region where transcription of the coding region is
terminated.
The elements of the expression cassette in particular are functionally linked
to each
other.
Specific examples of the expression cassette comprise or consist of the
nucleic acid
sequence of any one of SEQ ID NOs: 1 to 5. Respective expression elements are
also
shown in Figure 2 wherein the different elements of the expression cassettes
are
indicated. In particular, H54, H53, H52, and H540 are parts of the locus
control region
of the human a-globin or 3-globin gene cluster. Following this locus control
region, the
functional part of the human Ay globin promoter (Ay-Prom) is indicated.
Thereafter, a
coding sequence or cloning site for introduction of a coding sequence (CS) and
a
transcription terminator region including a polyadenylation signal (ypA)
follow. At the
end of the expression cassette, the functional part of a 3' enhancer of the
human Ay
globin gene (Ay-Enh) is positioned.
In certain embodiments, the expression cassette does not comprise a 3-globin
intron 2,
in particular any intron of a 3-globin gene or any other globin gene.
CA 02978659 2017-09-05
WO 2016/156404
PCT/EP2016/056926
8
The human Ay globin promoter
The expression cassette uses a functional part of the human Ay globin promoter
for
enabling and controlling expression of the coding region, in particular the
polypeptide of
interest. The functional part of the human Ay globin promoter is in particular
positioned
upstream of the coding region. It is functionally linked to the coding region
and allows
and controls transcription thereof. In certain embodiments, the functional
part of the
human Ay globin promoter encompasses a transcription initiation site where
transcription of the premature mRNA starts. Furthermore, the functional part
of the
human Ay globin promoter may also comprise at least part of a 5' untranslated
region
(5' UTR), in particular at least part of the 5' UTR of the human Ay globin
gene. In
specific embodiments, the functional part of the human Ay globin promoter
encompasses at least that part of the human Ay globin gene which allows
transcription
of the human Ay globin mRNA. In certain embodiments, the functional part of
the
human Ay globin promoter comprises a CCAAT box. In particular, the functional
part of
the human Ay globin promoter comprises or consists of nucleotides -299 to -26,
especially nucleotides -299 to +36, nucleotides -384 to -26, or nucleotides -
384 to +36,
with respect to the transcription initiation site, of the human Ay globin
gene. In
particular, the functional part of the human Ay globin promoter comprises and
especially
consists of the nucleic acid sequence of position 1123 to 1542 of SEQ ID NO:
1. It is
2 0 also possible to use shorter fragments of the human Ay globin promoter
which are still
functional. The person skilled in the art is capable of determining suitable
functional
parts of the human Ay globin promoter. In particular, methods for determining
the
activity of a promoter sequence are known in the art and described in the
examples,
below.
Alternatively, a homologue of said functional part of the human Ay globin
promoter may
be used according to the present invention. Said homologue preferably is at
least 85
%, preferably at least 90 %, at least 95 %, at least 97 %, at least 98 % or at
least 99 %
identical with one of the nucleic acid sequences defined above over its entire
length. In
certain embodiments, the homologue has the same or substantially the same
function
and/or activity as the functional part of the Ay globin promoter from which it
is derived,
and in particular provides an expression rate of the coding region which
reaches at
least 75%, preferably at least 80%, at least 85% or at least 90% of the
expression rate
reached by using the functional part of the Ay globin promoter from which it
is derived
under the same conditions.
The locus control region
The locus control region is functionally linked to the promoter region and is
capable to
modulate and in particular enhance the activity of the functional part of the
human Ay
CA 02978659 2017-09-05
WO 2016/156404
PCT/EP2016/056926
9
globin promoter. The locus control region in particular is positioned upstream
of the
promoter region.
In certain preferred embodiments, the locus control region or a functional
part thereof
of the human 6-globin gene cluster is used. According to the art, the human 6-
globin
locus control region encompasses four erythroid specific DNase I
hypersensitivity sites
termed HS1 to HS4 located 6 to 20 kbp upstream of the first globin gene of
this gene
cluster, i.e. the c-globin gene. In particular HS2 is responsible for
controlling expression
of the globin genes and is considered to constitute a major functional
component of the
locus control region. HS2 of the human 6-globin locus control region is
subdivided into
a core element and further modulatory subdomains, wherein the core element is
positioned between the modulatory subdomains M1 and M2. The core element is
the
minimal region of the 6-globin locus control region which is capable of
enhancing the
promoter activity of the human Ay globin promoter.
In a preferred embodiment, the locus control region comprises the core element
of the
DNAse I hypersensitivity site 2 (HS2) of the human 6-globin gene cluster. In
particular,
the core element of HS2 of the human 6-globin gene cluster has the nucleic
acid
sequence of position 906 to 939 of SEQ ID NO: 1. In certain embodiments, the
locus
control region comprises or consists of the core element of H52 and the two
adjacent
modulatory subdomains M1 and M2, i.e. the M1-core-M2 element of H52 of the
human
6-globin gene cluster. Said M1-core-M2 element may have the nucleic acid
sequence
of position 742 to 995 of SEQ ID NO: 1. It hence includes the core region of
H52
having the nucleic acid sequence of position 906 to 939 of SEQ ID NO: 1.
In a further embodiment, the locus control region comprises at least a
functional part of
the hypersensitivity site 2 (H52) of the human 6-globin gene cluster which
comprises
the nucleic acid sequence of position 741 to 1109 of SEQ ID NO: 1. This
functional part
of H52 comprises the M1-core-M2 element and an additional nucleic acid
sequence
directly downstream thereof.
In certain embodiments, the locus control region which comprises at least a
functional
part of H52 of the human 6-globin gene cluster further comprises at least a
part of the
hypersensitivity site 3 (H53) of the human 6-globin gene cluster. In
particular, the H53
or part thereof is positioned upstream of the H52 or part thereof in the locus
control
region of the expression cassette. The H53 or part thereof in particular
comprises or
consists of the nucleic acid sequence of position 310 to 735 of SEQ ID NO: 1.
Furthermore, the locus control region may also comprise the hypersensitivity
site 4
(H54) or a part thereof of the human 6-globin gene cluster, which in
particular is
positioned upstream of H52 and H53, if present. in certain embodiments, H54 or
the
part thereof comprises or consists of the nucleic acid sequence of position 13
to 294 of
SEQ ID NO: 1. Hence, the locus control region of the expression cassette
according to
CA 02978659 2017-09-05
WO 2016/156404
PCT/EP2016/056926
the invention may comprise, in downstream direction, optionally at least a
part of HS4,
optionally at least a part of HS3, and at least a functional part of HS2 of
the human 13-
globin gene cluster. In alternative embodiments, the locus control region does
not
comprise the hypersensitivity site 3 (HS3) of the human 13-globin gene
cluster.
5 In particular embodiments, the locus control region has a nucleic acid
sequence
selected from the group consisting of position 13 to 1109 of SEQ ID NO: 1,
position 20
to 819 of SEQ ID NO: 2, position 18 to 386 of SEQ ID NO: 3 and position 13 to
266 of
SEQ ID NO: 4.
In another embodiment, the locus control region comprises at least a
functional part of
10 the hypersensitivity site 40 (H540) of the human a-globin gene cluster.
The part of
H540 in particular comprises or consists of the core element of H540 which may
have
the nucleic acid sequence of position 24 to 278 of SEQ ID NO: 5. In
particular, H540 or
the part thereof comprises or consists of the nucleic acid sequence of
position 7 to 372
of SEQ ID NO: 5.
Furthermore, in certain embodiments a locus control region can be used
comprising or
consisting of a nucleic acid sequence which is a homologue of one of the above
locus
control regions. In particular, said homologue has a sequence identity of at
least 90%,
preferably at least 95%, at least 97%, at least 98% or at least 99% with one
of the
above locus control regions over the entire length, and/or has the same or
substantially
the same function as the locus control region from which it is derived. In
preferred
embodiments, the homologue locus control region provides an expression rate of
the
coding region which reaches at least 75%, preferably at least 80%, at least
85% or at
least 90% of the expression rate reached by using the locus control region
from which
it is derived under the same conditions.
The coding region
The coding region of the expression cassette comprises a nucleic acid
sequences
coding for a product of interest, in particular a polypeptide of interest,
which is to be
expressed by the expression cassette. The expression of the nucleic acid
sequences of
the coding region is regulated by the promoter region and hence, is
functionally linked
3 0 thereto. When the expression cassette, optionally present in a vector,
is introduced into
a suitable host cell, said host cell produces a product, in particular a
polypeptide,
encoded by the nucleic acid sequences of the coding region.
The coding region of the expression cassette in particular contains or
consists of a
nucleic acid sequence coding for a polypeptide of interest.
CA 02978659 2017-09-05
WO 2016/156404
PCT/EP2016/056926
11
The polypeptide of interest may be any polypeptide, including proteins. The
polypeptide
may be of any origin, including mammalian- and human-derived polypeptides as
well
as artificial polypeptides. In certain embodiments, the polypeptide comprises
one or
more glycosylation sites and in particular is a glycosylated polypeptide such
as a
glycoprotein or a part thereof. antibodies or derivatives or parts thereof;
peptide
hormones, gonadotropins such as FSH (follicle-stimulating hormone), CG
(chorionic
gonadotropin), LH (luteinizing hormone) and TSH (thyroid-stimulating hormone)
including all isoforms and variants thereof; erythropoietin; blood clotting
factors such as
factor VII, VIII, IX or von Willebrand factor; lysosomal enzymes and
cytokines.
Furthermore, the polypeptide of interest may be selected from the group
consisting of
any of the protein molecule of the group of cytokines and their receptors, for
instance
the tumor necrosis factors TNF-alpha and TNF-beta; renin; human growth hormone
and bovine growth hormone; growth hormone releasing factor; parathyroid
hormone;
thyroid stimulating hormone; lipoproteins; alpha-1-antitrypsin; insulin A-
chain and B-
chain; gonadotrophins, e.g. follicle stimulating hormone (FSH), luteinizing
hormone
(LH), thyrotrophin, and human chorionic gonadotrophin (hCG); calcitonin;
glucagon;
clotting factors such as factor VIIIC, factor IX, factor VII, tissue factor
and von
Willebrands factor; anti-clotting factors such as protein C; atrial
natriuretic factor; lung
surfactant; plasminogen activators, such as urokinase, human urine and tissue-
type
plasminogen activator; bombesin; thrombin; hemopoietic growth factor;
enkephalinase;
human macrophage inflammatory protein; a serum albumin such as human serum
albumin; mullerian- inhibiting substance; relaxin A-chain and B-chain;
prorelaxin;
mouse gonadotropin-associated peptide; vascular endothelial growth factor;
receptors
for hormones or growth factors; integrin; protein A and D; rheumatoid factors;
neurotrophic factors such as bone-derived neurotrophic factor, neurotrophin-3,
-4, -5, -
6 and nerve growth factor-beta; platelet-derived growth factor; fibroblast
growth factors;
epidermal growth factor; transforming growth factor such as TGF-alpha and TGF-
beta;
insulin-like growth factor-I and -II; insulin-like growth factor binding
proteins; CD
proteins such as CD-3, CD-4, CD-8 and CD-19; erythropoietin (EPO);
osteoinductive
factors; immunotoxins; a bone morphogenetic protein; an interferon such as
interferon-
alpha, -beta, and - gamma; colony stimulating factors (CSF's), e.g. M-CSF, GM-
CSF
and G-CSF; interleukins (IL's), e.g. IL-1 to IL-12; superoxide dismutase; T-
cell
receptors; surface membrane proteins; decay accelerating factor; antibodies
and
immunoadhesins; glycophorin A; and mucin proteins such as MUC1.
In certain embodiments, the polypeptide of interest is an antibody or a part
or derivative
thereof. In particular, the polypeptide of interest may be the heavy chain or
the light
chain of an antibody or a part thereof. Furthermore, the polypeptide of
interest may be
a part or derivative of an antibody selected from the group consisting of (i)
Fab
fragments, monovalent fragments consisting of the variable region and the
first
constant domain of each the heavy and the light chain; (ii) F(ab)2 fragments,
bivalent
CA 02978659 2017-09-05
WO 2016/156404
PCT/EP2016/056926
12
fragments comprising two Fab fragments linked by a disulfide bridge at the
hinge
region; (iii) Fd fragments consisting of the variable region and the first
constant domain
CH1 of the heavy chain; (iv) Fv fragments consisting of the heavy chain and
light chain
variable region of a single arm of an antibody; (v) scFv fragments, Fv
fragments
consisting of a single polypeptide chain; (vi) (Fv)2 fragments consisting of
two Fv
fragments covalently linked together; (vii) a heavy chain variable domain; and
(viii)
multibodies consisting of a heavy chain variable region and a light chain
variable region
covalently linked together in such a manner that association of the heavy
chain and
light chain variable regions can only occur intermolecular but not
intramolecular. In
embodiments wherein the expression cassette includes a coding region coding
for an
antibody or a part or derivative thereof, the locus control region in
particular comprises
at least a part of HS2 of the human 13-globin gene cluster, preferably at
least a part of
HS2 and at least a part of HS3 of the human 13-globin gene cluster or at least
a part of
HS2 and at least a part of HS4 of the human 13-globin gene cluster, especially
at least a
part of HS2 and at least a part of HS3 and at least a part of HS4 of the human
13-globin
gene cluster.
In certain embodiments, the coding region encodes more than one polypeptide,
in
particular two polypeptides. In these embodiments, the coding region may
contain two
or more separate nucleic acid sequences which transcribe into separate mRNAs,
each
having its own transcription initiation site, transcription termination site
and
polyadenylation signal. Alternatively, the coding region may contain a nucleic
acid
sequence which transcribe into an mRNA which comprises two or more separate
coding nucleic acid sequences which each encode a separate polypeptide. In
these
embodiments, the coding region may comprise one or more internal ribosomal
entry
sites, one for each coding nucleic acid sequence in addition to the first one.
These
internal ribosomal entry sites allow the translation of more than one
polypeptide from a
single transcript. In certain embodiments, the coding region encodes two
polypeptides,
in particular the heavy chain and the light chain of an antibody.
In certain embodiments, the coding region comprises a nucleic acid sequence
coding
for a signal peptide which in particular comprises an extracellular
localization signal.
The nucleic acid sequence coding for a signal peptide may be the only coding
sequence of the coding region or may be present in addition to further coding
sequences, such as those nucleic acid sequences coding for a polypeptide as
described above. The signal peptide in particular induces a secretory
expression of the
polypeptide of interest encoded by the coding region. The signal peptide may
be
cleaved off from the remaining polypeptide during the expression. The signal
peptide in
particular is positioned upstream of the other coding nucleic acid sequences
comprised
in the coding region or upstream of the cloning site, in particular at the
beginning of the
coding region. Furthermore, the nucleic acid sequence coding for the signal
peptide is
CA 02978659 2017-09-05
WO 2016/156404
PCT/EP2016/056926
13
positioned in frame with the other coding nucleic acid sequences comprised in
the
coding region.
In particular embodiments, the coding region comprises the nucleic acid
sequence
coding for a polypeptide of interest.
In certain embodiments, the coding region does not comprise a reporter gene or
a
selectable marker gene. In further embodiments, the coding region does not
comprise
a nucleic acid sequence coding for a globin protein or a part thereof
comprising at least
20 consecutive amino acids of a globin protein.
The cloning site
In certain embodiments, the expression cassette comprises a cloning site for
integrating a nucleic acid sequence. The cloning site may be present in the
expression
cassette instead of the coding region and may serve for introducing said
nucleic acid
sequence into the expression cassette. Furthermore, the cloning site may be
present in
the expression cassette in addition to the coding region, in particular in
embodiments
wherein the coding region only comprises a nucleic acid sequence coding for a
signal
peptide.
The cloning site present in the expression cassette is suitable for
introducing a coding
region, in particular a nucleic acid coding for a polypeptide of interest,
into the
expression cassette. Suitable cloning sites and methods for introducing
nucleic acid
fragments into other nucleic acid molecules such as expression cassettes or
vectors
are commonly known in the art. In certain embodiments, the cloning site
comprises at
least one, in particular at least two, at least three, at least four or at
least five
recognition sequences of restriction enzymes. Suitable restriction enzymes and
their
recognition sequences are known in the art. Exemplary restriction enzymes are
EcoRI,
EcoRV, HindIII, BamHI, Xbal, Pvul, Kpnl, BstXI, Xmal, Smal, Notl, Xhol and
Clal. An
exemplary nucleic acid sequence of a multiple cloning site is represented by
the
nucleic acid sequence of position 1559 to 1664 of SEQ ID NO: 1.
The transcription terminator region
In certain embodiments, the expression cassette comprises a transcription
terminator
region. The transcription terminator region is functionally linked with the
promoter
region and terminates the transcription of the coding region. It is positioned
downstream of the coding region and/or cloning site.
In specific embodiments, the transcription terminator region comprises a
transcription
termination site and/or a polyadenylation signal. The polyadenylation signal
may be
any polyadenylation signal which is capable of inducing polyadenylation of the
CA 02978659 2017-09-05
WO 2016/156404
PCT/EP2016/056926
14
premature mRNA in eukaryotic cells, in particular in human cells. It may
comprise or
consist of the nucleic acid sequence of position 1725 to 1730 of SEQ ID NO: 1
or a
homologue thereof.
The enhancer region
In certain embodiments, the expression cassette comprises an enhancer region,
in
particular a 3' enhancer region. The 3' enhancer region is positioned
downstream of the
coding region and/or cloning site and downstream of the transcription
terminator
region, if present. It is functionally linked with the promoter region and
enhances
expression of the coding region. The enhancer region in particular comprises
or
1 0 consists of at least a functional part of the 3' enhancer of the human
Ay globin gene. In
certain embodiments, the enhancer region comprises or consists of the nucleic
acid
sequence of position 2136 to 2881 of SEQ ID NO: 1 or a homologue thereof. In
certain
embodiments, the homologue enhancer region provides an expression rate of the
coding region which reaches at least 75%, preferably at least 80%, at least
85% or at
least 90% of the expression rate reached by using the enhancer region from
which it is
derived under the same conditions.
The vector comprising the expression cassette
In one aspect, the present invention pertains to a vector comprising the
expression
cassette according to the invention. The vector may be any vector suitable for
2 0 transferring the expression cassette into a host cell. Respective
vectors are known in
the art. In particular, the vector is adapted for transfer into eukaryotic
cells, such as
mammalian cells, in particular human cells.
In addition to the expression cassette, the vector may comprise further
elements. For
example, the vector may comprise one or more selection markers. In certain
embodiments, at least one of the selection markers is suitable for selecting
host cells
comprising the vector, in particular eukaryotic host cells, such as mammalian
host
cells, in particular human host cells, against host cells not comprising the
vector.
Suitable examples of the selection markers are genes which provide resistance
against
an antibiotic compound. Furthermore, the vector may comprise elements suitable
for
amplifying it in a prokaryotic host cell such as E. coil cells. Such elements
for example
include an origin of replication such as Col El On and a prokaryotic selection
marker
such as a gene providing resistance against a bactericide, e.g. ampicillin.
In certain embodiments, the vector is a circular or linear double-stranded
DNA, in
particular a circular double-stranded DNA.
CA 02978659 2017-09-05
WO 2016/156404
PCT/EP2016/056926
In certain embodiments, the vector comprises the expression cassette with the
coding
region comprising a nucleic acid sequence coding for a polypeptide of
interest.
The selectable marker gene
In certain embodiments, the vector further comprises a selectable marker gene.
The
5 selectable marker gene does not need to be functionally linked with the
elements of the
expression cassette. The selectable marker gene allows for selection of host
cells
which comprise the vector. Cells containing the vector preferably are
cultivated in the
presence of a suitable selection agent which reduces or inhibits proliferation
of cells not
comprising the selectable marker gene.
10 In specific embodiments, the selectable marker gene is an amplifiable
selectable
marker gene which allows amplification of the marker gene and co-amplification
of the
expression cassette which is present on the same vector. When using an
amplifiable
selectable marker gene, amplification of the expression cassette in
transfected cells in
particular is achieved by stepwise cultivation of the cells in the presence of
increasing
15 concentrations of the selection agent. In certain embodiments, the
selectable marker
gene encodes a dihydrofolate reductase (DHFR), such as an antifolate resistant
DHFR
variant, and the corresponding selection agent is an antifolate, such as
methotrexate.
Further examples of suitable amplifiable selectable marker genes and their
corresponding selection agents are neomycin resistance gene (e.g.
aminoglycoside
phosphotransferase) and geneticin (G418); puromycin N-acetyl-transferase and
puromycin; metallothionein and cadmium; CAD (carbamoyl-phosphate synthetase :
aspartate transcarbamylase : dihydroorotase) and N-phosphoacetyl-L-aspartate;
adenosine-deaminase and Xyl-A- or adenosine, 21deoxycoformycin; AMP
(adenylate)-
deaminase and adenine, azaserin, coformycin; UMP-synthase and 6-azauridine,
pyrazofuran; IMP 5'-dehydrogenase and mycophenolic acid; xanthine-guanin-
phosphoribosyl transferase and mycophenolic acid with limiting xanthine;
mutant
HGPRTase or mutant thymidine kinase and hypoxanthine, aminopterine and
thymidine
(HAT); thymidylate synthetase and 5-fluorodeoxyuridine; P-glycoprotein 170
(MDR1)
and adriamycin, vincristin, colchicine; ribonucleotide reductase and
aphidicoline;
glutamine synthetase and methionine sulphoximine (MSX); asparagine synthetase
and
6-aspartylhydroxamate, albizziin, 5'azacytidine; argininosuccinate synthetase
and
canavanin; ornithine decarboxylase and a-difluoromethyl-ornithine; HMG-CoA-
reductase and compactin; N-acetylglucosaminyl transf erase and tunicamycin;
threonyl-
tRNA synthetase and borrelidin; and Na K -ATPase and ouabain.
CA 02978659 2017-09-05
WO 2016/156404
PCT/EP2016/056926
16
The host cell comprising the expression cassette or the vector
In a further aspect, the present invention provides a host cell comprising the
expression
cassette according to the invention or the vector according to the invention.
The host
cell may be any cell suitable for transfection with the expression cassette or
vector and
in particular suitable for production of the polypeptide of interest. In
certain
embodiments, the host cell is derived from an established expression cell
line. The host
cell in particular is a eukaryotic cell, such as a mammalian cell, in
particular a human
cell, or a cell derived therefrom. In particular, the host cell is a blood
cell, such as a
white blood cell, blood precursor cell or leukemia cell, or a cell derived
therefrom. In
certain embodiments, the host cell is a cell of leukocyte origin.
In specific embodiments, the host cell is derived from human myeloid leukaemia
cells.
Specific examples of host cells are K562, NM-F9, NM-D4, NM-H9D8, NM-H9D8-E6,
NM-H9D8-E6Q12, GT-2X, GT-5s and cells derived from anyone of said host cells.
K562 is a human myeloid leukemia cell line present in the American Type
Culture
Collection (ATCC CCL-243). The remaining cell lines are derived from K562
cells and
have been selected for specific glycosylation features. Cell lines derived
from K562 can
be cultivated and maintained under the well-known conditions suitable for
K562. All
these cell lines except for K562 cells were deposited according to the
Budapest treaty.
Information on the deposition can be found at the end of the specification.
Exemplary host cells are also described, for example, in WO 2008/028686. In
certain
embodiments, the host cell is optimized for expression of glycoproteins having
a
specific glycosylation pattern. In particular, the codon usage in the coding
region and/or
the promoter and the further elements of the expression cassette or vector are
compatible with and in particular optimized for the type of host cell used.
In certain embodiments, the host cell is an isolated host cell. In specific
embodiments,
the host cell is not present in the human or animal body.
The host cell may be transiently or stably transfected with the expression
cassette or
vector according to the invention. Stable transfection is preferred, in
particular by
integration of the expression cassette into the genome of the host cell.
Transfection
methods for stable or transient transfection are commonly known in the art. In
certain
embodiments, the host cell is transfected with the vector which comprises the
expression cassette with the coding region comprising a nucleic acid sequence
coding
for a polypeptide of interest.
CA 02978659 2017-09-05
WO 2016/156404
PCT/EP2016/056926
17
The production method
According to a further aspect, the present invention provides a method for
recombinantly producing a polypeptide of interest, comprising the steps of
(a) providing a host cell which comprises an expression cassette comprising,
functionally linked to each other,
(i) a locus control region comprising at least a functional part of the locus
control region of the human 13-globin gene cluster or the human a-globin
gene cluster;
(ii) a promoter region comprising at least a functional part of the promoter
of
the human Ay globin gene; and
(iii) a coding region comprising a nucleic acid sequence encoding the
polypeptide of interest;
(b) culturing the host cell under conditions at which the host cell expresses
the
polypeptide of interest; and
(c) isolating the polypeptide of interest.
The host cell in particular comprises an expression cassette as defined
herein, having
one or more of the elements defined herein.
Suitable conditions for culturing the host cells and expressing the
polypeptide of
interest depend on the specific host cell, vector and expression cassette used
in the
method. The skilled person can readily determine suitable conditions and they
are also
already known in the art for a plurality of host cells. In certain
embodiments, the host
cell is transfected with a vector comprising the expression cassette and
further
comprising a selectable marker gene. In these embodiments, the culturing
conditions in
step (b) may include the presence of a corresponding selection agent in the
cell culture
medium.
Isolation of the polypeptide of interest in particular refers to the
separation of the
polypeptide of interest from the remaining components of the cell culture. In
certain
embodiments, the coding region of the expression cassette further comprises a
nucleic
acid sequence coding for a signal peptide for secretory expression, and in
step (b) the
polypeptide of interest is secreted by the host cell. In these embodiments,
step (c) in
particular comprises separating the cell culture medium comprising the
polypeptide of
interest from the host cells, for example by centrifugation, and separating
the
polypeptide of interest from some or most of the components of the cell
culture
CA 02978659 2017-09-05
WO 2016/156404
PCT/EP2016/056926
18
medium, for example by chromatographic methods. Suitable methods and means for
isolating the polypeptide of interest are known in the art and can be readily
applied by
the skilled person.
In certain embodiments, the method for producing a polypeptide of interest
further
comprises after step (c) the step of
(d) formulating the polypeptide of interest as a pharmaceutical composition.
Formulating the polypeptide of interest as a pharmaceutical composition in
particular
comprises exchanging the buffer solution or buffer solution components of the
composition comprising the polypeptide of interest. Furthermore, the
formulation step
may include lyophilization of the polypeptide of interest. In particular, the
polypeptide of
interest is transferred into a composition only comprising pharmaceutically
acceptable
ingredients.
Numeric ranges described herein are inclusive of the numbers defining the
range. The
headings provided herein are not limitations of the various aspects or
embodiments of
this invention which can be read by reference to the specification as a whole.
According to one embodiment, subject matter described herein as comprising
certain
steps in the case of methods or as comprising certain ingredients in the case
of
compositions refers to subject matter consisting of the respective steps or
ingredients.
It is preferred to select and combine specific aspects and embodiments
described
herein and the specific subject-matter arising from a respective combination
of specific
embodiments also belongs to the present disclosure.
FIGURES
Figure 1 shows the structure of the human globin gene clusters including the
locus
control region (LCR) with the different DNase hypersensitivity sites (HS) and
the
different globin genes. A: human 6-globin gene cluster on chromosome 11; B:
human
a-globin gene cluster on chromosome 16.
Figure 2 shows the elements of exemplary expression cassettes as used in the
vectors
pHBG1A-E. HS: DNase hypersensitivity site; Ay-Prom: promoter of the Ay globin
gene;
CS: coding sequence / cloning site; ypA: polyadenylation signal of the Ay
globin gene;
Ay-ENh: 3 enhancer of the Ay globin gene.
Figure 3 shows the factor VII protein yield obtained after transient
transfection of
different vectors comprising the coding sequence of factor VII. Vectors
comprising the
expression cassettes shown in Figure 2 with the coding sequence of factor VII
introduced into the cloning site and a gene encoding DHFR as amplifiable
selectable
marker were transiently transfected into NM-H9D8 cells. Total yield of factor
VII was
CA 02978659 2017-09-05
WO 2016/156404
PCT/EP2016/056926
19
determined after cultivation. pEFdhfrmut(-): control vector with factor VII
coding
sequence. The results of three independent experiments are shown.
Figure 4 shows a comparison of stable transfection of a vector according to
the
invention and a control vector encoding an antibody. NM-H9D8-E6Q12 cells were
stably transfected with the control vector pEF or the vector pHB according to
the
invention. Both vectors comprise a coding sequence for an antibody and a gene
encoding DHFR as amplifiable selectable marker. For amplification of the
vector in the
cells, the selection pressure, i.e. the concentration of the selection agent
methotrexate
in the culture medium, was stepwise increased. The graph shows the maximum
selection pressure which was possible for the respective vector after a given
cultivation
time. A higher possible selection pressure (methotrexate concentration)
indicates a
stronger amplification of the vector in the transfected cells, which should
result in a
higher production of the protein of interest.
Figure 5 shows the pool productivity of the stably transfected cells of Figure
4. The
antibody production in picogram per cell per day is shown for the different
selection
pressures for the vector according to the invention and the control vector.
Figure 6 shows the increase in productivity of the stably transfected cells of
Figure 4
by amplification of the vector due to the selection pressure. The antibody
production in
picogram per cell per day is shown for the different selection pressures for
the starting
cell pool, for the cell pool after amplification and for single cell clones
after
amplification. A: control vector pEF; B: vector pHB according to the
invention.
EXAMPLES
Example 1: Construction of vectors comprising the human Ay globin promoter and
elements of the locus control regions of the human globin gene clusters
For construction of the globin vectors, the enhancer and promoter regions of a
parent
vector (e.g. pEF having a puromycin or neomycin resistance gene or a dhfr gene
as
selectable marker) were removed. The human Ay globin promoter, polyadenylation
signal and 3 enhancer regions and different constructs of the locus control
regions of
the human globin gene clusters were synthesized and cloned into the vector at
the
appropriate sites. Fig. 2 shows exemplary constructs of the expression
cassettes of the
constructed vectors. Then a nucleic acid sequence coding for a polypeptide of
interest
was introduced into the cloning site.
Example 2: Transient transfection of the globin vectors
Transient transfection was performed with Lipofectamine LTX and PIu5TM
Reagent
according to the manufacturer's instructions. Briefly, 2 x 105 cells were
seeded in 6-well
CA 02978659 2017-09-05
WO 2016/156404
PCT/EP2016/056926
plates during their logarithmic growth phase. Plasmid DNA was diluted in Opti-
MEM I
Reduced Serum Medium and PlusTm-Reagent. After an incubation time (15 min),
Lipofectamine LTX was added to the solution. After further incubation (30
min), the
mixture was dripped in the cell suspension. Expression was analyzed after 72
hours by
5 ELISA. Higher protein titers were achieved by the vectors pHBG1Cdhfr,
pHBG1Ddhfr
and pHBG1Edhfr in comparison to the vector pEFdhfrmut(-) (Fig. 3).
Example 3: Stable transfection of the globin vectors
Transfection of the cell line NM-H9D8 was performed by nucleofection
(NucleofectorTM
Technology, Amaxa) using plasmid DNA of the two expression plasmids coding for
the
10 antibody heavy and light chain, respectively (both linearized) according
to the
manufacturer's instructions. For selection and amplification of antibody
producing
pools, methotrexate and puromycin were added at increasing concentrations and
pools
were screened for secretion of active antibody molecules.
Pools transfected with pHB plasmids could be amplified in a shorter time
period (Fig. 4)
15 and led to higher protein levels (Fig. 5) which could be confirmed for
resulting single
cell clones, respectively (Fig. 6).
CA 02978659 2017-09-05
WO 2016/156404
PCT/EP2016/056926
21
Identification of the deposited biological material
The cell lines DSM ACC 2606 and DSM ACC 2605 were deposited at the DSMZ -
Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Mascheroder Weg
1 b, 38124 Braunschweig (DE) by Nemod Biotherapeutics GmbH & Co. KG, Robert-
Rossle-Str. 10, 13125 Berlin (DE) on August 14, 2003. Glycotope is entitled to
refer to
these biological materials since they were in the meantime assigned from Nemod
Biotherapeutics GmbH & Co. KG to Glycotope GmbH.
The cell lines DSM ACC 2806, DSM ACC 2807, DSM ACC 2856, DSM ACC 2858 and
DSM ACC 3078 were deposited at the DSMZ - Deutsche Sammlung von
Mikroorganismen und Zellkulturen GmbH, InhoffenstraBe 7B, 38124 Braunschweig
(DE) by Glycotope GmbH, Robert-Rossle-Str. 10, 13125 Berlin (DE) on the dates
indicated in the following table.
Name of the Accession Depositor Date of Deposition
Cell Line Number
NM-F9 DSM ACC 2606 Nemod Biotherapeutics August 14, 2003
NM-D4 DSM ACC 2605 Nemod Biotherapeutics August 14, 2003
NM-H9D8 DSM ACC 2806 Glycotope GmbH September 15, 2006
NM-H9D8-E6 DSM ACC 2807 Glycotope GmbH October 5, 2006
NM-H9D8- DSM ACC 2856 Glycotope GmbH August 8, 2007
E6Q12
GT-2x DSM ACC 2858 Glycotope GmbH September 7, 2007
GT-5s DSM ACC 3078 Glycotope GmbH July 28, 2010
